Vaccines and Immunotherapy for Non-small Cell Lung Cancer

Journal of Thoracic Oncology

Volumn 5, Issue 12, 2010, Pages S463-S465

  Morgensztern, Daniel ^a,b   Goodgame, Boone ^a   Govindan, Ramaswamy ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Washington University in St Louis School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

ARTICLE; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; PATHOLOGY;

CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS;

MLCS; MLOWN;

EID: 79952476209     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000391367.63882.79     Document Type: Article

References (6)

1. Nemunaitis, J, Sterman, D, Jablons, D, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 96 (2004), 326–331.
2. Nemunaitis, J, Dillman, RO, Schwarzenberger, PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 24 (2006), 4721–4730.
3. Butts, C, Murray, N, Maksymiuk, A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23 (2005), 6674–6681.
4. Parikh, PK, Wang, Y, Ranade, AA, et al. Oral talactoferrin extends survival in patients with refractory NSCLC in a randomized, placebo-controlled, phase 2 trial. J Clin Oncol (Meeting Abstracts), 25, 2007, 7540.
5. Lynch, TJ, Bondarenko, IN, Luft, A, et al. Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts), 28, 2010, 7531.
6. Vansteenkiste, J, Zielinski, M, Linder, A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts), 25, 2007, 7554.